Fundamental Analysis of PHATHOM PHARMACEUTICALS INC(NASDAQ:PHAT) stock

Fundamental Rating

PHAT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. PHAT has a bad profitability rating. Also its financial health evaluation is rather negative. PHAT is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

PHAT had negative earnings in the past year.

PHAT had a negative operating cash flow in the past year.

In the past 5 years PHAT always reported negative net income.

PHAT had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -69.18%, PHAT is doing worse than 68.04% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-69.18%
ROE	N/A
ROIC	N/A

ROA(3y)-81.55%

ROA(5y)-77.52%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PHAT has a Gross Margin (19.85%) which is comparable to the rest of the industry.

The Profit Margin and Operating Margin are not available for PHAT so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	19.85%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PHAT does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for PHAT has been increased compared to 1 year ago.

PHAT has more shares outstanding than it did 5 years ago.

PHAT has a better debt/assets ratio than last year.

2.2 Solvency

PHAT has an Altman-Z score of -4.18. This is a bad value and indicates that PHAT is not financially healthy and even has some risk of bankruptcy.

PHAT's Altman-Z score of -4.18 is on the low side compared to the rest of the industry. PHAT is outperformed by 63.40% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-4.18

ROIC/WACCN/A

WACC7.81%

2.3 Liquidity

A Current Ratio of 7.83 indicates that PHAT has no problem at all paying its short term obligations.

With a decent Current ratio value of 7.83, PHAT is doing good in the industry, outperforming 79.38% of the companies in the same industry.

A Quick Ratio of 7.80 indicates that PHAT has no problem at all paying its short term obligations.

With a decent Quick ratio value of 7.80, PHAT is doing good in the industry, outperforming 78.87% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	7.83
Quick Ratio	7.8

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

PHAT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.45%, which is quite good.

EPS 1Y (TTM)9.45%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-59.55%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PHAT will show a very strong growth in Earnings Per Share. The EPS will grow by 21.32% on average per year.

PHAT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 353.72% yearly.

EPS Next Y-38.12%

EPS Next 2Y0.07%

EPS Next 3Y15.75%

EPS Next 5Y21.32%

Revenue Next Year10213.7%

Revenue Next 2Y1909.14%

Revenue Next 3Y857.9%

Revenue Next 5Y353.72%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PHAT. In the last year negative earnings were reported.

Also next year PHAT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as PHAT's earnings are expected to grow with 15.75% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y0.07%

EPS Next 3Y15.75%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for PHAT!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PHATHOM PHARMACEUTICALS INC

NASDAQ:PHAT (5/31/2024, 7:00:00 PM)

After market: 9.42 0 (0%)

9.42

-0.77 (-7.56%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap551.45M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-69.18%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	19.85%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	7.83
Quick Ratio	7.8
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)9.45%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-38.12%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

PHATHOM PHARMACEUTICALS INC (PHAT)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens